Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 79

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 6
Chunk 79
---
,004,150            39,987,013
Brian Meltzer              9,742,250            40,138,528
Meeting of Directors

The number of meetings our board of directors (including committee meetings of directors) held during the year ended June 30, 2025 and the number of meetings attended by each director were:

                          Board Meetings               Audit Committee                    Remuneration          
                                                           Meetings                    Committee Meetings       
----------------------------------------------------------------------------------------------------------------
Director                 A                   B   A                   B         A                       B        
Geoffrey Kempler         5                   5        —                   —          —                       —  
Lawrence Gozlan          5                   4        —                   —          —                       —  
Peter Marks              5                   5   3                   2         0                       0        
Brian Meltzer            5                   5   3                   3         0                       0        

A   =   Number of meetings held during the time the director held office or was a member of the committee.
----------------------------------------------------------------------------------------------------------

B   =   Number of meetings attended
-----------------------------------

—   =   Not a member of the relevant committee
----------------------------------------------

46

B.   Compensation
-----------------

The remuneration report is set out under the following main headings:

a)   Principles used to determine the nature and amount of remuneration
-----------------------------------------------------------------------

b)   Details of remuneration
----------------------------

c)   Share-based compensation
-----------------------------

d)   Key management personnel disclosure
----------------------------------------

e)   Employment contracts of Directors and other key management personnel
-------------------------------------------------------------------------

a)   Principles used to determine the nature and amount of remuneration
-----------------------------------------------------------------------

Remuneration policy

Remuneration of all Executive and Non-Executive Directors, Officers and Employees of our Group is determined by the Board following recommendation by the Remuneration Committee.

We are committed to remunerating Senior Executives and Executive Directors in a manner that is market- competitive and consistent with “Best Practice” including the interests of Shareholders. Remuneration packages are based on fixed and variable components, determined by the Executives’ position, experience and performance, and may be satisfied via cash or equity.

In accordance with the approval of our shareholders at our 2004 annual general meeting of shareholders, the aggregate amount available per annum for the remuneration of our non-executive directors for their services (payable in cash, ordinary shares or options) is A$1,250